Old Web
English
Sign In
Acemap
>
authorDetail
>
Maroof Hasan
Maroof Hasan
Bristol-Myers Squibb
Enasidenib
Medicine
Internal medicine
IDH2
Mutant
3
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
2021
Lancet Oncology
Courtney Dinardo
Andre C. Schuh
Eytan M. Stein
Pau Montesinos
Andrew Wei
Stéphane de Botton
Amer M. Zeidan
Amir T. Fathi
Hagop M. Kantarjian
John M. Bennett
Mark G. Frattini
Patricia Martin-Regueira
Frederik Lersch
J Gong
Maroof Hasan
Paresh Vyas
Hartmut Döhner
Show All
Source
Cite
Save
Citations (1)
Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial
2021
Blood
Courtney D. DiNardo
Pau Montesinos
Andre C. Schuh
Cristina Papayannidis
Paresh Vyas
Andrew H. Wei
Amer M. Zeidan
Iryna Bluemmert
Xin Yu
Maroof Hasan
Patricia Martin-Regueira
Stéphane de Botton
Show All
Source
Cite
Save
Citations (0)
Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression
2021
Blood
Douglas Ra Silveira
Prodromos Chatzikyriakou
Olena Yavorska
Sarah Mackie
Roan Hulks
Paulina Siejka-Zielińska
Anna Corby
Alastair L. Smith
B. L. Brown
Marlen Metzner
Thomas A. Milne
Virginie Penard-Lacronique
Chun-Xiao Song
Maroof Hasan
Anjan Thakurta
Paresh Vyas
Skirmantas Kriaucionis
Lynn Quek
Show All
Source
Cite
Save
Citations (0)
1